Senior VP & Chief Medical Officer of GlycoMimetics Edwin Rock Buys 81% More Shares [Yahoo! Finance]
GlycoMimetics, Inc. (GLYC)
Last glycomimetics, inc. earnings: 5/1 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.glycomimetics.com/investor-relations
Company Research
Source: Yahoo! Finance
NASDAQ:GLYC ) Senior VP & Chief Medical Officer, Edwin Rock, recently bought US$79k worth of stock, for US$0.26 per share. While that isn't the hugest buy, it actually boosted their shareholding by 81%, which is good to see. See our latest analysis for GlycoMimetics The Last 12 Months Of Insider Transactions At GlycoMimetics Notably, that recent purchase by Senior VP & Chief Medical Officer Edwin Rock was not the only time they bought GlycoMimetics shares this year. Earlier in the year, they paid US$1.38 per share in a US$90k purchase. That means that even when the share price was higher than US$0.33 (the recent price), an insider wanted to purchase shares. Their view may have changed since then, but at least it shows they felt optimistic at the time. We always take careful note of the price insiders pay when purchasing shares. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth bu
Show less
Read more
Impact Snapshot
Event Time:
GLYC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLYC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLYC alerts
High impacting GlycoMimetics, Inc. news events
Weekly update
A roundup of the hottest topics
GLYC
News
- GlycoMimetics, Inc. (NASDAQ: GLYC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- GlycoMimetics, Inc. (NASDAQ: GLYC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- GlycoMimetics, Inc. (NASDAQ: GLYC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- GlycoMimetics, Inc. (NASDAQ: GLYC) had its "neutral" rating re-affirmed by analysts at HC Wainwright.MarketBeat
- GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) [Yahoo! Finance]Yahoo! Finance
GLYC
Earnings
- 5/9/24 - Miss
GLYC
Analyst Actions
- 6/4/24 - HC Wainwright
GLYC
Sec Filings
- 6/26/24 - Form 8-K
- 6/24/24 - Form 4
- 6/20/24 - Form 4
- GLYC's page on the SEC website